﻿<?xml version="1.0" encoding="UTF-8"?>
<ArticleSet>
  <Article>
    <Journal>
      <PublisherName>Society of Diabetic Nephropathy Prevention</PublisherName>
      <JournalTitle>Journal of Nephropathology</JournalTitle>
      <Issn>2251-8363</Issn>
      <Volume>5</Volume>
      <Issue>4</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2016</Year>
        <Month>10</Month>
        <DAY>01</DAY>
      </PubDate>
    </Journal>
    <ArticleTitle>Preventive effects of betulinic acid on streptozotocinnicotinamide induced diabetic nephropathy in male mouse</ArticleTitle>
    <FirstPage>128</FirstPage>
    <LastPage>133</LastPage>
    <ELocationID EIdType="doi">10.15171/jnp.2016.24</ELocationID>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName>Akram</FirstName>
        <LastName>Ahangarpour</LastName>
      </Author>
      <Author>
        <FirstName>Ali Akbar</FirstName>
        <LastName>Oroojan</LastName>
      </Author>
      <Author>
        <FirstName>Layasadat</FirstName>
        <LastName>Khorsandi</LastName>
      </Author>
      <Author>
        <FirstName>Razieh</FirstName>
        <LastName>Shabani</LastName>
      </Author>
      <Author>
        <FirstName>Shahnaz</FirstName>
        <LastName>Mojaddami</LastName>
      </Author>
    </AuthorList>
    <PublicationType>Journal Article</PublicationType>
    <ArticleIdList>
      <ArticleId IdType="doi">10.15171/jnp.2016.24</ArticleId>
    </ArticleIdList>
    <History>
    </History>
    <Abstract>Background: Diabetic nephropathy is defined as a progressive decline in glomerular filtration rate, accompanied by proteinuria. Betulinic acid (BA) employs in the treatment and management of diabetes. Objectives: This study was designed to evaluate the preventive effects of BA on streptozotocinnicotinamide (STZ-NA) induced diabetic nephropathy in male mouse. Materials and Methods: In this experimental study, 60 adult male NMRI mice (20-25 g) were obtained. Type 2 diabetes induced by intraperitoneal (IP) injection of a single dose of STZ (65 mg/kg) 15 minutes after an IP administration of NA (120 mg/kg). Then, mice were divided into six groups; control, diabetes, diabetes + BA (10, 20 and 40 mg/kg), and diabetes + metformin (200 mg/kg). Twenty-four hours after the last drug administrations, plasma samples were obtained and maintained at −20°C for albumin, blood urea nitrogen (BUN) and creatinine (Cr) measurements. Renal tissue was removed, fixed in 10% formalin solution and stained with hematoxylin and eosin. Results: Plasma albumin level decreased in diabetic mice (P &lt; 0.05) and increased in diabetic BA 10, 20, 40 mg/kg and metformin treated mice versus to diabetes group. BUN increased in diabetes (P &lt; 0.001), and administration of BA 10, 20, 40 mg/kg and metformin showed a significant decrease in BUN of diabetic treated mice. Plasma Cr levels increased in diabetes (P &lt; 0.01) but, BA 10, 20, 40 mg/kg and metformin decreased this enhancement of plasma Cr levels. Renal histopathology indicated normal appearances reduced in diabetic mice and BA or metformin administration improved them. Conclusion: BA has a preventing effect on diabetic nephropathy by amelioration of plasma albumin, BUN, Cr and renal histology changes during diabetic situation. </Abstract>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Betulinic acid</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Diabetic nephropathy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Metformin</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Diabetes mellitus</Param>
      </Object>
    </ObjectList>
  </Article>
</ArticleSet>